AU2006301582B2 - Matrix metalloproteinase 11 vaccine - Google Patents

Matrix metalloproteinase 11 vaccine Download PDF

Info

Publication number
AU2006301582B2
AU2006301582B2 AU2006301582A AU2006301582A AU2006301582B2 AU 2006301582 B2 AU2006301582 B2 AU 2006301582B2 AU 2006301582 A AU2006301582 A AU 2006301582A AU 2006301582 A AU2006301582 A AU 2006301582A AU 2006301582 B2 AU2006301582 B2 AU 2006301582B2
Authority
AU
Australia
Prior art keywords
mmp
encoding
polypeptide
ltb
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006301582A
Other languages
English (en)
Other versions
AU2006301582A1 (en
Inventor
Luigi Aurisicchio
Gennaro Ciliberto
Nicola La Monica
Domenico Lazzaro
Federica Mori
Daniela Peruzzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD Italia SRL
Original Assignee
MSD Italia SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSD Italia SRL filed Critical MSD Italia SRL
Publication of AU2006301582A1 publication Critical patent/AU2006301582A1/en
Application granted granted Critical
Publication of AU2006301582B2 publication Critical patent/AU2006301582B2/en
Assigned to MSD ITALIA S.R.L. reassignment MSD ITALIA S.R.L. Request for Assignment Assignors: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
AU2006301582A 2005-10-07 2006-10-03 Matrix metalloproteinase 11 vaccine Ceased AU2006301582B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72449805P 2005-10-07 2005-10-07
US60/724,498 2005-10-07
PCT/EP2006/009536 WO2007042169A2 (en) 2005-10-07 2006-10-03 Matrix metalloproteinase 11 vaccine

Publications (2)

Publication Number Publication Date
AU2006301582A1 AU2006301582A1 (en) 2007-04-19
AU2006301582B2 true AU2006301582B2 (en) 2011-10-13

Family

ID=37451271

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006301582A Ceased AU2006301582B2 (en) 2005-10-07 2006-10-03 Matrix metalloproteinase 11 vaccine

Country Status (9)

Country Link
US (2) US8106176B2 (enExample)
EP (1) EP1934246B8 (enExample)
JP (1) JP5361386B2 (enExample)
CN (1) CN101365715B (enExample)
AT (1) ATE521629T1 (enExample)
AU (1) AU2006301582B2 (enExample)
CA (1) CA2623531C (enExample)
ES (1) ES2370040T3 (enExample)
WO (1) WO2007042169A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
EP2342334A4 (en) * 2008-09-29 2012-03-14 Univ Pennsylvania VACCINES DIRECTED TO TUMOR VESSEL MARKERS
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
ES2844123T3 (es) * 2009-08-13 2021-07-21 Acceleron Pharma Inc Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos
JP5823405B2 (ja) 2009-11-04 2015-11-25 ザ ユニバーシティ オブ ブリティッシュ コロンビア 核酸含有脂質粒子および関連方法
WO2013059922A1 (en) 2011-10-25 2013-05-02 The University Of British Columbia Limit size lipid nanoparticles and related methods
JP6605446B2 (ja) 2013-03-15 2019-11-13 ザ ユニバーシティ オブ ブリティッシュ コロンビア 形質移入用の脂質ナノ粒子および関連方法
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
RS64397B1 (sr) 2015-03-27 2023-08-31 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raznih tumora (seq id 25 - mrax5-003)
WO2018156106A1 (en) * 2017-02-22 2018-08-30 Ding Enyu An mrna cancer vaccine encoding human gm-csf fused to multiple tandem epitopes
CN115003820A (zh) * 2019-10-08 2022-09-02 爱科霍拉有限公司 用于眼部治疗的组合物和方法
US20240199725A1 (en) 2021-04-16 2024-06-20 Korea University Research And Business Foundation Human antibody targeting covid-19 virus
GB202117583D0 (en) * 2021-12-06 2022-01-19 Cambridge Entpr Ltd Protein expression
CN116590263A (zh) * 2023-07-02 2023-08-15 广州庆毅生物医药科技有限公司 一种重组蛋白、单克隆抗体及其检测试剂盒和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052301A2 (en) * 2002-12-10 2004-06-24 Isis Pharmaceuticals, Inc. Modulation of matrix metalloproteinase 11 expression
WO2005077977A2 (en) * 2004-02-11 2005-08-25 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Carcinoembryonic antigen fusions proteins and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
GB9112553D0 (en) * 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
WO1997044056A1 (en) * 1996-05-23 1997-11-27 Xoma Corporation Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
HUP0201019A2 (en) 1999-04-26 2002-08-28 Leuven K U Res & Dev Synthetic gene for expressing active retroviral protein in eukaryotes
JP2003511061A (ja) * 1999-10-08 2003-03-25 アクティブ バイオテック エイビー 変更された化学結合体化特性を有するａｂ５毒素ｂサブユニット変異体
GB9930768D0 (en) * 1999-12-29 2000-02-16 Pfizer Ltd Composition
CA2422882A1 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
CN1889963A (zh) * 2003-10-10 2007-01-03 宝德杰克特疫苗有限公司 方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052301A2 (en) * 2002-12-10 2004-06-24 Isis Pharmaceuticals, Inc. Modulation of matrix metalloproteinase 11 expression
WO2005077977A2 (en) * 2004-02-11 2005-08-25 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Carcinoembryonic antigen fusions proteins and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Fromigue, O. et al. International Journal of Cancer 2003, 106(3), 355-363 *
Fu, L. et al. J. Biol. Chem. 2005, 280(30), 27856-27865 *
Noel, A. et al. Oncogene 2000, 19, 1605-1612 *
Wu, E. et al. Journal of Cellular Biochemistry 2001, 82(4), 549-555 *

Also Published As

Publication number Publication date
ATE521629T1 (de) 2011-09-15
CN101365715A (zh) 2009-02-11
WO2007042169A2 (en) 2007-04-19
ES2370040T3 (es) 2011-12-12
JP5361386B2 (ja) 2013-12-04
US20090155298A1 (en) 2009-06-18
US8106176B2 (en) 2012-01-31
US20120177679A1 (en) 2012-07-12
CA2623531C (en) 2013-12-10
US8492522B2 (en) 2013-07-23
AU2006301582A1 (en) 2007-04-19
CA2623531A1 (en) 2007-04-19
EP1934246B8 (en) 2012-02-08
EP1934246B1 (en) 2011-08-24
CN101365715B (zh) 2013-03-27
JP2009509553A (ja) 2009-03-12
EP1934246A2 (en) 2008-06-25
WO2007042169A3 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
US8492522B2 (en) Matrix metalloproteinase 11 vaccine
DK2155243T3 (en) Compositions and methods comprising KLK3, PSCA, or antigen FOLH1
AU2007306368B2 (en) Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
US20040241686A1 (en) Her2/neu target antigen and use of same to stimulate an immune response
KR20050010040A (ko) 면역원성 조성물
CA2555013C (en) Carcinoembryonic antigen fusions and uses thereof
EA034928B1 (ru) Конструкция нуклеиновой кислоты для индукции иммунного ответа у субъекта против клеток, сверхэкспрессирующих теломеразу, и ее применение
KR102158923B1 (ko) 암 백신
NZ543922A (en) Synthetic gene encoding human carcinoembryonic antigen and uses thereof
CN101001869B (zh) 癌胚抗原融合物和其用途
MXPA06009202A (en) Carcinoembryonic antigen fusions proteins and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MSD ITALIA S.R.L.

Free format text: FORMER OWNER WAS: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA

MK14 Patent ceased section 143(a) (annual fees not paid) or expired